Albendazole Oxide

Albendazole Oxide

SCHEMBL1649240

CCC[S+]([O-])c1ccc2nc(NC(=O)OC)[nH]c2c1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.64
TUBB4A P04350 8/20 0.64
TUBB P07437 8/20 0.64
TUBA3C P0DPH7 8/20 0.64
TUBA1B P68363 8/20 0.64
TUBA4A P68366 8/20 0.64
TUBB4B P68371 8/20 0.64
TUBB3 Q13509 8/20 0.64
TUBB2A Q13885 8/20 0.64
TUBB8 Q3ZCM7 8/20 0.64
TUBA3E Q6PEY2 8/20 0.64
TUBA1A Q71U36 8/20 0.64
TUBA1C Q9BQE3 8/20 0.64
TUBB6 Q9BUF5 8/20 0.64
TUBB2B Q9BVA1 8/20 0.64
TUBB1 Q9H4B7 8/20 0.64
CYP1A2 P05177 6/20 0.64
HIF1A Q16665 5/20 0.64
TSHR P16473 2/20 0.64
CYP2D6 P10635 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Albendazole Oxide SCHEMBL17968582 1.00 LMNA (0.64) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL30580728 1.00 LMNA (0.64) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL321413 0.91 LMNA (0.55) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL29564405 0.91 LMNA (0.55) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL20657154 0.91 LMNA (0.60) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL3175532 0.90 LMNA (0.54) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11266586 0.88 LMNA (0.53) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11258288 0.84 LMNA (0.58) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11662850 0.83 LMNA (0.53) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL9370388 0.82 LMNA (0.66) LMNATUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0224257-A1 Stabilized benzimidazole derivatives SYNTEX (U.S.A.) INC. (US) 1987-06-03 EP claimed
CN-114249749-B Conversion method of marbofloxacin formate 天象生物药业邢台有限责任公司 2024-03-22 CN disclosed
CN-114249749-A Conversion method of marbofloxacin formate 天象生物药业邢台有限责任公司 2022-03-29 CN disclosed
EP-2576778-B1 TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS UNIV KYOTO (JP) 2017-08-09 EP disclosed
US-9273364-B2 Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms KYOTO UNIVERSITY (JP) 2016-03-01 US disclosed
US-20130137099-A1 TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS KYOTO UNIVERSITY (JP) 2013-05-30 US disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 US disclosed
EP-0224257-A1 Stabilized benzimidazole derivatives SYNTEX (U.S.A.) INC. (US) 1987-06-03 EP disclosed